Point72 Asset Management L.P. Grows Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Point72 Asset Management L.P. lifted its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 26.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,426,599 shares of the company’s stock after acquiring an additional 710,936 shares during the quarter. Point72 Asset Management L.P. owned approximately 2.60% of Centessa Pharmaceuticals worth $57,396,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after purchasing an additional 660 shares during the period. Barclays PLC raised its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after acquiring an additional 5,316 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after acquiring an additional 6,000 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $162,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $12.59 on Friday. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -8.23 and a beta of 1.53. The business has a 50 day moving average of $13.56 and a 200 day moving average of $15.59. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. On average, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares in the company, valued at $5,273,100.81. This represents a 14.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the transaction, the general counsel now directly owns 105,386 shares in the company, valued at $1,705,145.48. This trade represents a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 171,398 shares of company stock valued at $2,697,422 over the last three months. Insiders own 7.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CNTA. Morgan Stanley reissued an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price target for the company. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an “overweight” rating and a $38.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $27.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.